CA
NAMS icon

Clearstead Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Clearstead Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58K Buy
+76
New +$2.5K ﹤0.01% 2390
2025
Q4 		– Sell
-88
Closed -$2.5K – 3077
2025
Q3 		$2.5K Hold
88
– – ﹤0.01% 2385
2025
Q2 		$1.59K Buy
+88
New +$1.6K ﹤0.01% 2371

Other funds holding NAMS

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Clearstead Advisors's NAMS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 76 shares worth $2.58K. The stake represents ﹤0.01% of the portfolio and ranks #2390 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in NAMS as recently as Q3 2025.

Clearstead Advisors first reported a position in NAMS in Q2 2025 and has held it in 3 quarters since. 66 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Clearstead Advisors held 76 shares of NewAmsterdam Pharma worth $2.58K as of Q2 2026.
  • NewAmsterdam Pharma was a new Clearstead Advisors position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2390 holding.
  • Clearstead Advisors first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 3 quarters since.
  • 66 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.